; finding. Sec. 382. Fees relating to over-the-counter drugs. Subtitle I—Other Provisions Sec. 391. Protecting access to biological products. Sec. 392. Orphan drug clarification. Sec. 393. Conditions of use for biosimilar biological products. Sec. 394. Clarifying the meaning of new chemical entity. Title IV—Revenue Provisions Sec. 401. Permanent extension of reduction in medical expense deduction floor. Sec. 402. Safe harbor for high deductible health plans without deductible for insulin. Sec. 403. Inclusion of certain over-the-counter medical products as qualified medical expenses. Title V—Miscellaneous Sec. 501. Payment for biosimilar biological products during initial period. Sec. 502. GAO study and report on average sales price. Sec. 503. Requiring prescription drug plans and MA–PD plans to report potential fraud, waste, and abuse to the Secretary of HHS. Sec. 504. Establishment of pharmacy quality measures under Medicare part D. Sec. 505. Improving coordination between the Food and Drug Administration and the Centers for Medicare & Medicaid Services. Sec. 506. Patient consultation in Medicare national and local coverage determinations in order to mitigate barriers to inclusion of such perspectives. Sec. 507. MedPAC report on shifting coverage of certain Medicare part B drugs to Medicare part D. Sec. 508. Requirement that direct-to-consumer advertisements for prescription drugs and biological products include truthful and non-misleading pricing information. Sec. 509. Chief Pharmaceutical Negotiator at the Office of the United States Trade Representative. Sec. 510. Waiving Medicare coinsurance for colorectal cancer screening tests. I Medicare Parts B and D A Medicare Part B Provisions 101. Improvements to Medicare site-of-service transparency Section 1834(t) of the Social Security Act ( 42 U.S.C. 1395m(t) ) is amended— (1) in paragraph (1)— (A) in the heading, by striking In general and inserting Site payment ; (B) in the matter preceding subparagraph (A)— (i) by striking or to and inserting , to